MX2022012004A - Metodo de construccion y aplicacion del vector de visualizacion genica del polipeptido de union especifica de antigeno. - Google Patents

Metodo de construccion y aplicacion del vector de visualizacion genica del polipeptido de union especifica de antigeno.

Info

Publication number
MX2022012004A
MX2022012004A MX2022012004A MX2022012004A MX2022012004A MX 2022012004 A MX2022012004 A MX 2022012004A MX 2022012004 A MX2022012004 A MX 2022012004A MX 2022012004 A MX2022012004 A MX 2022012004A MX 2022012004 A MX2022012004 A MX 2022012004A
Authority
MX
Mexico
Prior art keywords
antigen
binding polypeptide
specific binding
polypeptide gene
display vector
Prior art date
Application number
MX2022012004A
Other languages
English (en)
Inventor
Chen Zhou
Original Assignee
Ddbio Co Ltd Shang Hai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ddbio Co Ltd Shang Hai filed Critical Ddbio Co Ltd Shang Hai
Publication of MX2022012004A publication Critical patent/MX2022012004A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00—Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06—Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

En la presente solicitud se describe un método para construir un vector de visualización génica de un polipéptido de unión específico de antígeno; el método comprende el procesamiento mediante el uso de una endonucleasa de restricción que reconoce específicamente un sitio de restricción para obtener cuatro fragmentos de ácido nucleico que tienen extremos cohesivos específicos y luego permite que los fragmentos de ácido nucleico se unan direccionalmente; en la presente solicitud también se describen un vector de visualización génica de un polipéptido de unión específico de antígeno producido de acuerdo con el método y una biblioteca bacteriana; el método descrito en la presente solicitud se puede usar para seleccionar eficazmente polipéptidos de unión a antígeno específicos de antígeno o fragmentos de los mismos.
MX2022012004A 2020-03-27 2021-03-26 Metodo de construccion y aplicacion del vector de visualizacion genica del polipeptido de union especifica de antigeno. MX2022012004A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010231148 2020-03-27
PCT/CN2021/083246 WO2021190629A1 (zh) 2020-03-27 2021-03-26 抗原特异性结合多肽基因展示载体的构建方法与应用

Publications (1)

Publication Number Publication Date
MX2022012004A true MX2022012004A (es) 2022-10-21

Family

ID=77891335

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012004A MX2022012004A (es) 2020-03-27 2021-03-26 Metodo de construccion y aplicacion del vector de visualizacion genica del polipeptido de union especifica de antigeno.

Country Status (8)

Country Link
US (1) US12686948B2 (es)
EP (1) EP4130260A4 (es)
JP (1) JP7772379B2 (es)
KR (1) KR20220162151A (es)
CN (1) CN115362254A (es)
BR (1) BR112022019392A2 (es)
MX (1) MX2022012004A (es)
WO (1) WO2021190629A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022012005A (es) * 2020-03-27 2022-10-21 Ddbio Co Ltd Shang Hai Metodo para el despliegue de anticuerpo biespecifico en la superficie de celula de mamifero y vector.
US20240360436A1 (en) * 2021-03-31 2024-10-31 DDBio. Co., Ltd. Vector and method for screening functional antigen-binding protein
JP2024540099A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
CN117402902B (zh) * 2023-12-11 2024-04-16 温氏食品集团股份有限公司 引物组合物及其在制备t载体上的应用
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101210241A (zh) * 2006-12-27 2008-07-02 陕西超英生物科技有限公司 一种噬菌体基因工程抗体库基因组装的方法
WO2010059981A2 (en) * 2008-11-21 2010-05-27 Dgen Biotech Limited High complexity mammalian display library and methods of screening
NZ596603A (en) * 2009-05-29 2013-07-26 Morphosys Ag A collection of antibodies or fragments having properties relevant to developability
KR102115300B1 (ko) 2018-06-01 2020-05-26 재단법인 목암생명과학연구소 항체 라이브러리 및 이를 이용한 항체 스크리닝 방법

Also Published As

Publication number Publication date
EP4130260A1 (en) 2023-02-08
JP7772379B2 (ja) 2025-11-18
BR112022019392A2 (pt) 2022-11-16
JP2023518900A (ja) 2023-05-08
US12686948B2 (en) 2026-07-21
CN115362254A (zh) 2022-11-18
US20230124855A1 (en) 2023-04-20
WO2021190629A1 (zh) 2021-09-30
KR20220162151A (ko) 2022-12-07
EP4130260A4 (en) 2024-05-15

Similar Documents

Publication Publication Date Title
BR112022019392A2 (pt) Vetor de exibição de gene de polipeptídeo de ligação específico de antígeno, métodos para construir o mesmo e para triar um polipeptídeo de ligação específico de antígeno ou fragmentos do mesmo, bem como biblioteca bacteriana de exibição de gene de polipeptídeo de ligação específico de antígeno
Kotál et al. Modulation of host immunity by tick saliva
Tian et al. Synthetic N-terminal coding sequences for fine-tuning gene expression and metabolic engineering in Bacillus subtilis
Solieri et al. Next-generation sequencing and its potential impact on food microbial genomics
EP3118319B1 (en) Transcription activator-like effector assembly
CN113851186A (zh) 一种同源2型CRISPR/Cas基因编辑系统的构建方法
MX2021004898A (es) Enzima de crispr/cas12f y sistema novedosos.
JOP20200078B1 (ar) أجسام مضادة خاصة بـ cd47 وpd-l1
MY204975A (en) Complex surface-bound transposome complexes
MX2023003125A (es) Proteinas multiespecificas de union al antigeno.
Forouzan et al. Evaluation of nine popular de novo assemblers in microbial genome assembly
Wibberg et al. Improved genome sequence of the phytopathogenic fungus Rhizoctonia solani AG1-IB 7/3/14 as established by deep mate-pair sequencing on the MiSeq (Illumina) system
CN113495094B (zh) 分子质谱模型的训练方法、分子质谱模拟方法和计算机
Wibberg et al. Complete genome sequence of the cyanide-degrading bacterium Pseudomonas pseudoalcaligenes CECT5344
Xie et al. Evolutionary trajectory of the replication mode of bacterial replicons
WO2017109167A3 (en) Reconstitution of dna-end repair pathway in prokaryotes
De Franco et al. The Butantan Institute: history and future perspectives
Liu et al. Cyberbiosecurity: Advancements in DNA-based information security
US20170169161A1 (en) Method, device, and computer program for assembling pieces of chromosomes from one or several organisms
Walley et al. Dual use of peptide mass spectra: protein atlas and genome annotation
CN106011160A (zh) 一种细胞内支架结构及方法
CN104212827B (zh) 不依赖生物工程酶的快速分子克隆方法
GB2571979A8 (en) Graphics processing
Porter When One Size Doesn’t Fit All
Hollfelder et al. Just (protein) engineering? Editorial overview